Team
CEO
MARKUS THOR | CEO
Markus Thor, CEO, has 30 years of experience from the pharmaceutical/biotech industry and roles within R&D, business/corporate development and executive leadership functions. Previous positions include VP & Head of Business Development at Biovitrum, Senior Investment Advisor Life Sciences at Business Sweden, Chief Business Officer at Kancera and Chief Business Officer at XNK Therapeutics. Markus has a MSc in Chemistry from University of Umeå and an MBA from Stockholm School of Economics.
COO
ANNICA RÖNNBÄCK | COO
Annica Rönnbäck, COO, holds a Ph.D. from Umeå University and spent over a decade in neuroscience research at Karolinska Institutet before moving into biotech operations at Umeå Biotech Incubator. She joined QureTech Bio in 2018 as Project Coordinator and has served as Chief Operating Officer since 2021, a role she continues in at QureTech OncoBiome.
Senior Scientist
MARI BONDE | PHD
Mari Bonde, Senior Scientist, holds a Ph.D. in Molecular Biology from Umeå University. During her postdoctoral research at the university’s Department of Chemistry, she worked on newly synthesized small molecules effective against drug-resistant bacteria including MRSA and VRE. She has been part of QureTech since 2018.
Scientific Advisor
FREDRIK ALMQVIST | SCIENTIFIC ADVISOR
Fredrik Almqvist is currently Professor in Organic Chemistry at Umeå University Sweden and Director of Umeå Centre for Microbial Research (UCMR). His research program focuses on method development in organic synthesis and design of molecules that interact with macromolecules, in particular, inhibition of protein-protein interactions. Dr. Almqvist has been awarded the prestigious Göran Gustafsson Award by the Swedish Royal Academy of Sciences, Ulla and Stig Holmquist Science Prize in Organic Chemistry and the Norblad Ekstrand Medal in Chemistry. Author of 120+ peer-reviewed publications and founder of the company SpinChem AB (previously named Nordic ChemQuest AB).
Scientific Advisor
JÖRGEN JOHANSSON | PROFESSOR
Jörgen Johansson is Professor in Molecular Microbiology at the Department of Molecular Biology and Laboratory for Molecular Infection Medicine Sweden (MIMS) at Umeå University and a co-founder of QureTech Bio. The Johansson group uses the Gram-positive bacterial pathogen Listeria monocytogenes as a model system to study RNA-biology, stress-regulation and to identify novel antivirulence compounds. The group has identified and characterized several aspects of RNA regulation resulting in high impact publications (Cell, Nature, PNAS). The group recently described a blue-light receptor that Listeria uses to sense light and adjust its stress-response. Together with Prof. Almqvist, the Johansson group has identified several 2-pyridone compounds able to block Listeria virulence gene expression by binding the main transcriptional regulator. In 2010, Prof. Johansson received the prestigious European Research Council (ERC) Starting Grant.
Scientific Advisor
SVEN BERGSTRÖM | PROFESSOR
The Bergström group is studying the infectious and virulence properties of Borrelia spirochete and the intracellular parasite Chlamydia.
Board of Directors
Chairman
LENNART HANSSON | CHAIRMAN
Board member since 2023. Chairman of the Board since 2024.
Lennart Hansson is former head of Life Science Investments at Industrifonden, one of Sweden’s largest venture funds. Previously he has more than 30 years’ experience in the pharma and biotech industry in executive positions at KabiGen, Symbicom AB, AstraZeneca AB, Karolinska Development AB and BioVitrum AB and as CEO for Arexis AB. He has a PhD in Genetics from Umeå University.
Other current assignments: Hansson is chairman of the board of Cinclus Pharma Holding AB, Sixera Pharma AB and Ignitus AB, as well as board member of Medivir AB.
ULF BJÖRKLUND | BOARD MEMBER
Board member since 2023.
Ulf Björklund has more than 35 years of experience from the pharmaceutical industry from research, development and marketing of pharmaceuticals to diagnostics. Previous engagements include CEO of Aprea in oncology and CEO of OxyPharma in autoimmune diseases. Prior to that, he held several senior positions at Pharmacia in clinical research covering many therapeutic areas. Ulf Björklund has additional experience in organization partner collaborations, financing and communication with regulatory authorities in Europe and the USA.
Ulf is currently chairman of the board of Lipum AB and Stayble Therapeutics AB, CEO at UB-consulting AB, CMO at Redwood Pharma AB. Ulf has a Pharmacy degree at Uppsala University.
Board member
ERIK GOZZI | BOARD MEMBER
Board member since 2021.
Erik Gozzi is the CEO at Nascent Invest, an early-stage investor with a focus on the Life Science sector that invest in high performance teams with a unique position in a global strong revenue growth market.
Board member
MIKAEL SELLIN | BOARD MEMBER
Board member since 2024.
Mikael Sellin is professor of molecular medicine, with a focus on infection biology, at Uppsala University. He is also affiliated with Science for Life Laboratory (SciLifeLab) and Uppsala Antibiotic Center. Mikael´s research group studies mechanisms of bacterial pathogenesis and novel anti-infective therapies, using a combination of organoid modelling, bacterial genetics technologies, and live-cell imaging. Mikael has authored >60 peer-reviewed research articles. He has been awarded the Lennart Philipson Award, the Ingvar Carlsson Award, appointed SciLifeLab Fellow, and named one of Sweden´s Future Research Leaders (by SSF). Mikael, moreover, serves as director for research studies at the MedPharm domain of Uppsala University, and as board member of Kempestiftelserna.
Board member
FREDRIK ALMQVIST | BOARD MEMBER
Fredrik Almqvist is currently Professor in Organic Chemistry at Umeå University Sweden and Director of Umeå Centre for Microbial Research (UCMR). His research program focuses on method development in organic synthesis and design of molecules that interact with macromolecules, in particular, inhibition of protein-protein interactions. Dr. Almqvist has been awarded the prestigious Göran Gustafsson Award by the Swedish Royal Academy of Sciences, Ulla and Stig Holmquist Science Prize in Organic Chemistry and the Norblad Ekstrand Medal in Chemistry. Author of 120+ peer-reviewed publications and founder of the company SpinChem AB (previously named Nordic ChemQuest AB).
Scientific Advisors
Professor
MATTHEW CHAPMAN | PROFESSOR
Matthew Chapman is Professor of Molecular, Cellular and Developmental Biology at University of Michigan, Ann Arbor. He received his Ph.D. from Indiana University in 1999 and was a Keck and NIH Fellow at Washington University in St. Louis from 1999- 2003. He is a specialist within protein mis-folding and amyloid formation.
QureTech OncoBiome is an affiliate company of QureTech Bio
QURETECH ONCOBIOME AB
Tvistevägen 48
907 36 UMEÅ
Org.no. 559576-9430
CONTACT
markus.thor@quretech.com
annica.ronnback@quretech.com
info@quretech.com
QureTech is a part of
